Skip to main content
DaehanPharmaceutical logo

DaehanPharmaceutical — Investor Relations & Filings

Ticker · 023910 ISIN · KR7023910003 KO Manufacturing
Open in API
Filings indexed 297 across all filing types
Latest filing 2021-02-26 Proxy Solicitation & In…
Country KR South Korea
Listing KO 023910

About DaehanPharmaceutical

https://www.dhnp.co.kr/

Daehan Nupharm is a pharmaceutical company engaged in the research, development, and manufacturing of a diverse portfolio of healthcare products. The company's business is structured around four core areas: human pharmaceuticals, offering a range of therapeutic treatments; animal health products for both companion and livestock animals; advanced bio-pharmaceuticals, with a focus on next-generation technologies like cell therapy; and health functional foods. Established initially in the animal health sector, the company leverages its dedicated Central and Bio Research Institutes to drive innovation and develop solutions for global markets. The R&D efforts concentrate on strengthening technological capabilities and advancing new treatment modalities.

Recent filings

Filing Released Lang Actions
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 1% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (often filed under the Financial Services Commission/Korea Exchange) used to solicit shareholder votes for an upcoming Annual General Meeting (AGM). It contains details about the meeting, the agenda (approval of financial statements, director appointments, etc.), and proxy voting procedures. While it includes financial statements, these are provided as part of the proxy solicitation materials for the AGM, not as a standalone annual report or audit report. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2021-02-26 Korean
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Daehan Pharmaceutical. It outlines the date, location, and agenda items (such as approval of financial statements, election of directors, and remuneration limits). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2021-02-17 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 1% confidence The document is a formal announcement from '대한약품' (Daehan Pharmaceutical) regarding the decision to pay cash dividends. It specifies the dividend amount per share (400 KRW), the dividend record date (2020-12-31), and the board resolution date (2021-02-10). This fits the definition of a 'Notice of Dividend Amount' (DIV) as it provides specific details regarding dividend payments to shareholders.
2021-02-10 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (Daehan Pharmaceutical) announcing a significant change in financial structure (revenue/profit fluctuation of 30% or more). This is a standard disclosure requirement for listed companies in Korea to report material financial changes before the final audit is completed. It provides key financial highlights and the reasons for the change, fitting the definition of an Earnings Release (ER) as it serves as an initial announcement of financial results. FY 2020
2021-02-10 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a short regulatory notice regarding the suspension of share registration (shareholder register closure) for the purpose of determining shareholders for the upcoming Annual General Meeting. It does not contain full financial statements or meeting materials, but rather serves as a formal regulatory announcement of a corporate action. Given it does not fit into specific categories like dividend announcements or share buybacks, it falls under the general regulatory filing category.
2020-12-14 Korean
분기보고서 (2020.09)
Interim / Quarterly Report Classification · 1% confidence The document is a 'Quarterly Report' (분기보고서) for Daihan Pharmaceutical Co., Ltd. (대한약품공업주식회사) covering the period from January 1, 2020, to September 30, 2020. It contains detailed financial information, business descriptions, management analysis, and governance details, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2020
2020-11-16 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.